A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer
- 240 Downloads
The aim of this study was to investigate the feasibility and efficacy of induction chemotherapy with gemcitabine and S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer.
Patients with locally advanced unresectable pancreatic cancer received four cycles of induction chemotherapy consisting of 30-min intravenous infusions of gemcitabine 1,000 mg/m2 on days 1 and 8 and oral S-1 40 mg/m2 twice daily on days 1–14 of a 21-day cycle. Those without disease progression received chemoradiotherapy of 30 Gy in ten fractions with 250 mg/m2 of gemcitabine on days 1 and 8.
A total of 20 patients were treated. Median follow-up time was 431 days (range 133–1,014 days). Four cycles of induction chemotherapy were completed in 18 patients, and 16 patients received chemoradiotherapy, which was completed without delay in all. Grade 3–4 toxicities associated with induction chemotherapy were neutropenia (50%); anemia (20%); thrombocytopenia (10%); febrile neutropenia (5%); nausea (10%); anorexia (10%); and vomiting, fatigue, dehydration, stomatitis, and rash (5%). Grade 3–4 toxicities among those receiving chemoradiotherapy were neutropenia (13%) and anemia (6%). Median progression-free survival was 8.1 months. Median overall survival was 14.4 months, with a 1-year survival rate of 54.2%.
The regimen of induction chemotherapy with gemcitabine and S-1 followed by chemoradiotherapy used in the present study demonstrated promising activity in locally advanced pancreatic cancer. Further consideration of radiation schedule and duration of induction chemotherapy is required to enhance the efficacy of this strategy.
KeywordsChemotherapy Pancreatic neoplasms Radiotherapy Gemcitabine S-1
The authors thank our patients and their families for their participation in this study. We appreciate our secretary, Ms Kayo Takei, for her devotion to the study.
- 3.Moertel CG, Frytak S, Hahn RG, O’Connell MJ, Reitemeier RJ, Rubin J et al (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48:1705–1710CrossRefPubMedGoogle Scholar
- 5.Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O et al (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19:1592–1599CrossRefPubMedGoogle Scholar
- 6.Loehrer PJ, Powell ME, Cardenes HR, Wagner L, Brell JM, Ramanathan RK et al. (2008) A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer. J Clin Oncol ASCO Annual Meeting Proceedings 26, Abstract 4506Google Scholar
- 10.Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W et al. (2007) Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol ASCO Annual Meeting Proceedings, Part I. 25(18S), LBA4513Google Scholar
- 11.Narahara H, Koizumi W, Hara T, Takagane A, Akiya T, Takagi M et al. (2007) Randomized phase III study of S-1 alone versus S-1 + cisplatin in the treatment for advanced gastric cancer (The SPIRITS trial) SPIRITS: S-1 plus cisplatin vs S-1 in RCT in the treatment for stomach cancer. J Clin Oncol ASCO Annual Meeting Proceedings, Part I; 25(18S), pp 4514Google Scholar
- 14.Ueno H, Okusaka T, Furuse J, Yamao K, Funakoshi A, Boku N et al. (2007) A multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer. J Clin Oncol ASCO Annual Meeting Proceedings Part I, 25(18S), pp 4550Google Scholar
- 18.Furuse J, Ishii H, Kawashima M, Nagase M, Nihei K, Nakachi K et al (2007) A phase I study of hypofractionated radiotherapy followed by systemic chemotherapy with full-dose gemcitabine in patients with unresectable locally advanced pancreatic cancer. Hepatogastroenterology 54:1575–1578PubMedGoogle Scholar
- 20.Mishra G, Butler J, Ho C, Melin S, Case LD, Ennever PR et al (2005) Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol 28:345–350CrossRefPubMedGoogle Scholar
- 22.Moureau-Zabotto L, Phélip JM, Afchain P, Mineur L, André T, Vendrely V et al (2008) Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. J Clin Oncol 26:1080–1085CrossRefPubMedGoogle Scholar
- 28.Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, GERCOR; GISCAD et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509–3516CrossRefPubMedGoogle Scholar